Does a preclinical randomized controlled trial, pRCT, resolve the gap between animal studies and human trials?
- 1 June 2021
- journal article
- editorial
- Published by Elsevier BV in Kidney International
- Vol. 99 (6), 1262-1264
- https://doi.org/10.1016/j.kint.2021.01.021
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas mice with proliferative lupus nephritis predicts low effect sizeKidney International, 2021
- International consensus definitions of clinical trial outcomes for kidney failure: 2020Kidney International, 2020
- The ARRIVE guidelines 2.0: Updated guidelines for reporting animal researchPLoS Biology, 2020
- The noblesse of kidney physiologyKidney International, 2019
- Kidney-on-a-chip: untapped opportunitiesKidney International, 2018
- Drug repurposing in kidney diseaseKidney International, 2018
- Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney diseaseKidney International, 2017
- Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemiaScience Translational Medicine, 2015